Whistleblower Policy

Whistleblower Contact

Quantum BioPharma Whistleblower Policy

Quantum BioPharma – Reward Program FAQ

Quantum BioPharma – Reward Program FAQ

Why is Quantum BioPharma Offering a Reward?

We are committed to protecting our shareholders and the integrity of the markets. If someone has tried to hire, ask, or pressure you to manipulate our stock, we want to know.

Who Can Report?

The following individuals/entities are not eligible to participate in the Reward Program:

  • Current directors, officers, or employees of Quantum BioPharma or its affiliates.
  • Members of law enforcement, regulatory agencies, or government officials acting in an official capacity.
  • Individuals who obtained information unlawfully or in violation of legal or professional duties.
  • Individuals who knowingly submit false, misleading, or fabricated information.

What Kind of information Qualifies?

  • The submission must provide definitive, credible, and verifiable proof that the reporting party was asked, hired, or otherwise induced to manipulate Quantum BioPharma’s stock.
  • The information must tangibly contribute to the final, non‑appealable judgment or binding settlement of ongoing or future litigation pursued by the Quantum BioPharma at trial, as determined by the Board of Directors in consultation with legal counsel.
  • Submissions must be original and not previously known to the Quantum BioPharma.

How Much is the Reward?

Up to USD$7 million, depending on the significance of the information.

How do I Submit Information?

Directly to reward@quantumbiopharma.com or call 1-833-571-1811

Can I Stay Anonymous?

Yes. Anonymous reports are accepted, though identifying yourself may be required in the litigation process and to receive a reward. Quantum Biopharma will use its best efforts to maintain the confidentiality of the whistleblower’s identity and will not disclose such identity without the whistleblower’s prior written consent.


However, if the information provided contributes to a final, non-appealable judgment or binding settlement in litigation pursued by Quantum Biopharma, and disclosure or testimony by the whistleblower is reasonably necessary under law or court order, Quantum Biopharma will notify the whistleblower as soon as possible and cooperate to minimize disclosure. The Company’s obligation to maintain confidentiality may be limited by legal, regulatory, or judicial requirements, but no disclosure will be made without the whistleblower’s approval except as expressly required by law, regulation, or court order.


In addition, Quantum Biopharma will not use any information provided by the whistleblower until the company and the whistleblower have agreed to compensation that the whistleblower is entitled to. Quantum Biopharma will treat all complaints as confidential and privileged to the fullest extent permitted by law.

Is this the Same as the SEC Whistleblower Program?

No. This program is separate and does not replace your right to report directly to the U.S. Securities and Exchange Commission (SEC) or to Canadian regulatory authorities’ whistleblower programs. You may be eligible for rewards under both programs.

Is the Reward Guaranteed?

No. Rewards are discretionary, depend on litigation outcomes, and require Board approval.

Disclaimer

This Reward Program is discretionary and subject to change or withdrawal at any time without notice. Reward eligibility does not depend on whether a whistleblower testifies, awards are based on the contribution and reliability of the information. Quantum Biopharma will not direct, script, or influence any witness testimony. Rewards are not payments for testimony. Payment of any reward is contingent upon legal review, Board approval, and the successful outcome of a final, non‑appealable judgment or binding settlement of ongoing or future litigation pursued by the Quantum BioPharma at trial to which the reported information materially contributes. Nothing in this FAQ creates a contractual right to payment. This program does not replace, restrict or limit rights under the U.S. Securities and Exchange Commission (SEC) Whistleblower Program or whistleblower programs operated by Canadian regulatory authorities, and individuals remain free to report directly to the SEC and Canadian regulatory authorities.